MTG201+ニボルマブの新興薬剤に関する洞察と市場予測：2032年

MTG201は、様々ながんに対応可能な独自の二重作用機序を有する新規の治験用遺伝子治療薬です。本薬候補は、当社独自のアデノウイルスベクター技術プラットフォームを活用し、不死化細胞/Dickkopf-3遺伝子（REIC/Dkk-3遺伝子）の発現が著しく低下しているがん細胞に、発現低下したREIC/Dkk-3遺伝子を導入します。その結果、がん細胞におけるREIC/Dkk-3遺伝子の発現が増加し、がん細胞で選択的に免疫原性細胞死が引き起こされます。同時に、腫瘍組織内の正常細胞成分におけるREIC/Dkk3遺伝子の発現増加は、樹状細胞とナチュラルキラー（NK）細胞を活性化することによって抗腫瘍免疫を促進する一方で、免疫抑制性の制御性T細胞（Treg）と骨髄由来抑制細胞（MDSC）を抑制します。このような新規の二重メカニズムに基づき、MTG201はニボルマブのようなチェックポイント阻害薬との相乗効果が期待できると考えられています。

テキサス州ヒューストンのベイラー医科大学で実施された第II相試験（NCT04013334）は、ニボルマブとの併用によるMTG201の腫瘍内投与の有効性、安全性、忍容性を評価するためにデザインされた非盲検単群試験です。本試験では、プラチンベースの全身化学療法が無効となった悪性中皮腫患者を最大12人まで登録しました。本試験の主要目的は併用療法の有効性を評価することであり、主要評価項目は客観的奏効率（ORR）です。

当レポートでは、主要7ヶ国におけるMTG201+ニボルマブ市場について調査し、市場の概要とともに、2024年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 悪性胸膜中皮腫（MPM）に対するMTG201+ニボルマブの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 MTG201+ニボルマブ市場評価

• MPMに対するMTG201+ニボルマブの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるMPMに対するMTG201+ニボルマブ市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: MTG201 + nivolumab, Clinical Trial Description, 2023
• Table 2: MTG201 + nivolumab, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: MTG201 + nivolumab Market Size in the 7MM, in USD million (2019-2032)
• Table 6: MTG201 + nivolumab Market Size in the US, in USD million (2019-2032)
• Table 7: MTG201 + nivolumab Market Size in Germany, in USD million (2019-2032)
• Table 8: MTG201 + nivolumab Market Size in France, in USD million (2019-2032)
• Table 9: MTG201 + nivolumab Market Size in Italy, in USD million (2019-2032)
• Table 10: MTG201 + nivolumab Market Size in Spain, in USD million (2019-2032)
• Table 11: MTG201 + nivolumab Market Size in the UK, in USD million (2019-2032)
• Table 12: MTG201 + nivolumab Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: MTG201 + nivolumab Market Size in the 7MM, USD million (2019-2032)
• Figure 2: MTG201 + nivolumab Market Size in the United States, USD million (2019-2032)
• Figure 3: MTG201 + nivolumab Market Size in Germany, USD million (2019-2032)
• Figure 4: MTG201 + nivolumab Market Size in France, USD million (2019-2032)
• Figure 5: MTG201 + nivolumab Market Size in Italy, USD million (2019-2032)
• Figure 6: MTG201 + nivolumab Market Size in Spain, USD million (2019-2032)
• Figure 7: MTG201 + nivolumab Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: MTG201 + nivolumab Market Size in Japan, USD million (2019-2032)

“"MTG201 + nivolumab Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MTG201 + nivolumab for malignant pleural mesothelioma (MPM) in the seven major markets. A detailed picture of the MTG201 + nivolumab for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the MTG201 + nivolumab for MPM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MTG201 + nivolumab market forecast analysis for MPM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in MPM.

Drug Summary:

MTG201 is novel investigational gene therapy with unique dual mechanisms of action capable of addressing a range of cancers. The drug candidate leverages the company's proprietary adenoviral vector technology platform to deliver the reduced expression in immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene is markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells. At the same time, increased expression of the REIC/Dkk3 gene in normal cell components in tumor tissue promotes antitumor immunity by activating dendritic cells and natural killer (NK) cells while suppressing immune-suppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSC). Based on these novel dual mechanisms, MTG201 is believed to be well-positioned to work synergistically with checkpoint inhibitors such as nivolumab.

The Phase II trial (NCT04013334), conducted at the Baylor College of Medicine in Houston, Texas, is an open-label, single-arm study designed to assess the efficacy, safety, and tolerability of intratumoral administration of MTG201 in combination with nivolumab. The trial enrolled up to twelve patients with malignant mesothelioma who have failed front-line systemic platin-based chemotherapy. The study's primary objective is to assess the efficacy of the treatment combination, with the primary endpoint being objective response rate (ORR).

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the MTG201 + nivolumab description, mechanism of action, dosage and administration, research and development activities in malignant pleural mesothelioma (MPM).
• Elaborated details on MTG201 + nivolumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MTG201 + nivolumab research and development activities in MPM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MTG201 + nivolumab.
• The report contains forecasted sales of MTG201 + nivolumab for MPM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for MPM.
• The report also features the SWOT analysis with analyst views for MTG201 + nivolumab in MPM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MTG201 + nivolumab Analytical Perspective by DelveInsight

• In-depth MTG201 + nivolumab Market Assessment

This report provides a detailed market assessment of MTG201 + nivolumab for malignant pleural mesothelioma (MPM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• MTG201 + nivolumab Clinical Assessment

The report provides the clinical trials information of MTG201 + nivolumab for MPM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for malignant pleural mesothelioma (MPM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MTG201 + nivolumab dominance.
• Other emerging products for MPM are expected to give tough market competition to MTG201 + nivolumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MTG201 + nivolumab in MPM.
• Our in-depth analysis of the forecasted sales data of MTG201 + nivolumab from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MTG201 + nivolumab in MPM.

Key Questions

• What is the product type, route of administration and mechanism of action of MTG201 + nivolumab?
• What is the clinical trial status of the study related to MTG201 + nivolumab in malignant pleural mesothelioma (MPM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MTG201 + nivolumab development?
• What are the key designations that have been granted to MTG201 + nivolumab for MPM?
• What is the forecasted market scenario of MTG201 + nivolumab for MPM?
• What are the forecasted sales of MTG201 + nivolumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to MTG201 + nivolumab for MPM?
• Which are the late-stage emerging therapies under development for the treatment of MPM?

Table of Contents

1. Report Introduction

2. MTG201 + nivolumab Overview in MPM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. MTG201 + nivolumab Market Assessment

• 5.1. Market Outlook of MTG201 + nivolumab in MPM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of MTG201 + nivolumab in the 7MM for MPM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of MTG201 + nivolumab in the United States for MPM
  • 5.3.2. Market Size of MTG201 + nivolumab in Germany for MPM
  • 5.3.3. Market Size of MTG201 + nivolumab in France for MPM
  • 5.3.4. Market Size of MTG201 + nivolumab in Italy for MPM
  • 5.3.5. Market Size of MTG201 + nivolumab in Spain for MPM
  • 5.3.6. Market Size of MTG201 + nivolumab in the United Kingdom for MPM
  • 5.3.7. Market Size of MTG201 + nivolumab in Japan for MPM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options